Established in
Headquartered in
China
Specializing in the Discovery,
Development, Production
and Commercialization
Innovative Oncology
Drugs
Core Products
in R&D Pipeline
Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide.
March 2022
NMPA-CDE Grants Priority Review Designation to Haihe Biopharma's Glumetinib
February 2022
The NDA for Haihe Biopharma’s Glumetinib has been accepted for review by the CDE.
January 2022
U.S. FDA Grants Orphan Drug Designation to Haihe Biopharma’s Glumetinib for Treatment of NSCLC with MET Genomic Aberration
March 2021
Haihe established its Japan office
July 2020
Haihe completed
Haihe completed worth
1.2 billion yuan Series B Funding
July 2020
Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Shanghai RMX Biopharma Co Ltd.
December 2019
Haihe established its US office
October 2019
Haihe’s Manufacturing Hub set foot in Taizhou China Medical City, with planned investment of 600 million yuan
September 2019
Haihe was recognized as Shanghai’s New & Hi-Tech Enterprise
April 2019
Haihe completed the first patient dosing of oral paclitaxel RMX3001 phase III clinical trial for advanced gastric cancer
February 2019
Haihe completed Haihe completed $136.6 million Series A Funding
January 2019
The pivotal Phase IIb clinical trial of first-class innovative drug Lucitanib for patients with thymic cancer completed the enrollment of the first patient in China
September 2018
Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical
March 2018
Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.
（Xinmin Evening News，2020-11-11）
.png)
.png)